ERBB2 and breast carcinoma: Ciravolo et al. found that HER2+ EVs bound the anti-HER2 therapeutic Trastuzumab, rendering breast cancer cells resistant to further Trastuzumab treatment, and a similar observation has been made for CD20+ EVs in lymphoma [27,49].